InvestorsHub Logo

pharma_trader

07/25/14 3:44 PM

#82214 RE: Bob Stocks #82209

ACST $1.00 also presenting tomorrow

"Phase II Open Label Trial results for prescription drug candidate, CaPre(R) to be presented on July 26, 2014 at 12:30 p.m.

LAVAL, Quebec, July 24, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (ACST) (APO.V), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that it has been selected to give an oral presentation at the 19th World Congress on Heart Disease. Pierre Lemieux, PhD, Acasti's Chief Operating Officer, will present CaPre(R) Phase II Open Label (COLT) trial results, previously announced in August 2013. A copy of the abstract will be available on Acasti's website upon conclusion of the conference:

http://finance.yahoo.com/news/acasti-announces-oral-presentation-colt-110000836.html